Detailed Analysis of the Scope and Claims of United States Patent 10,722,502
Introduction
United States Patent 10,722,502, titled "Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde," is a patent that delves into the crystalline forms of a specific compound, hereafter referred to as Compound 1. This patent is crucial for understanding the properties, preparation, and therapeutic applications of these crystalline forms.
Background
The patent is part of a series of continuations and priority claims, tracing back to provisional applications filed in 2014. It is associated with Global Blood Therapeutics, Inc., and focuses on the development of crystalline polymorphs of Compound 1, which is a compound with potential therapeutic applications, particularly in treating sickle cell anemia[4].
Scope of the Patent
The scope of the patent encompasses several key aspects:
Crystalline Polymorphs
The patent describes multiple crystalline polymorphs of the free base of Compound 1. These include Form I and Form II, among others. Each form is characterized by distinct physical and chemical properties.
Characterization Methods
The crystalline forms are characterized using various analytical techniques such as differential scanning calorimetry (DSC) and X-ray powder diffraction (XRPD). For example, Form II is characterized by an endothermic peak at approximately 97°C as measured by DSC and specific XRPD peaks at 13.37°, 14.37°, 19.95°, and 23.92° 2θ[4].
Therapeutic Applications
The patent outlines methods for treating oxygen deficiency associated with sickle cell anemia using the crystalline forms of Compound 1. It includes administering a therapeutically effective amount of one or more of these solvated crystal forms to subjects in need[4].
Claims of the Patent
The patent includes several claims that define the scope of the invention:
Composition Claims
Claims are made for the crystalline free base and solvate forms of Compound 1. These claims specify the different polymorphs, such as Form I and Form II, and their characteristic properties[4].
Method Claims
The patent claims methods for preparing these crystalline forms, including solvated crystal forms. It also includes methods for increasing oxygen affinity of hemoglobin S and treating oxygen deficiency associated with sickle cell anemia[4].
Specific Embodiments
The claims detail specific embodiments of the crystalline forms, including their XRPD patterns and thermal properties. For instance, Form II is characterized by specific XRPD peaks and the absence of thermal events below the endothermic peak at 97°C[4].
Patent Landscape
The patent landscape surrounding US 10,722,502 involves several related patents and applications:
Related Patents
Other patents, such as US 10,034,879, also deal with compounds that act as allosteric modulators of hemoglobin, highlighting the broader context of research in this area[2].
Continuation Applications
The patent is part of a series of continuation applications, indicating a continuous effort to refine and expand the claims related to Compound 1 and its crystalline forms[4].
Priority Claims
The patent claims priority to earlier provisional applications, demonstrating the evolution of the research and development process over several years[4].
Impact on Innovation and Industry
The patent's focus on specific crystalline forms and their therapeutic applications can significantly impact the pharmaceutical industry, particularly in the treatment of sickle cell anemia.
Therapeutic Advancements
The development of these crystalline forms can lead to more effective and stable therapeutic agents, improving treatment outcomes for patients with sickle cell anemia.
Intellectual Property
The detailed claims and characterizations in the patent help to establish a strong intellectual property position, which can influence licensing, collaboration, and litigation in the industry.
Key Metrics and Analysis
Patent Scope
The scope of the patent can be measured using metrics such as independent claim length and count. These metrics can indicate the breadth and specificity of the patent claims, which in turn can affect the patent's validity and enforcement[3].
Examination Process
The patent's history through the examination process can provide insights into how the claims were narrowed or broadened, reflecting the interactions between the patent office and the applicant[3].
Conclusion
United States Patent 10,722,502 is a comprehensive patent that details the crystalline polymorphs of a compound with significant therapeutic potential. The patent's scope includes detailed characterizations of these forms, methods for their preparation, and their therapeutic applications. Understanding the claims and the broader patent landscape is crucial for navigating the intellectual property and innovation landscape in the pharmaceutical industry.
Key Takeaways
- The patent describes multiple crystalline polymorphs of Compound 1, including Form I and Form II.
- Characterization methods include DSC and XRPD.
- Therapeutic applications focus on treating sickle cell anemia.
- The patent includes composition and method claims.
- The patent is part of a series of continuation applications and claims priority to earlier provisional applications.
- The development of these crystalline forms can significantly impact the treatment of sickle cell anemia.
Frequently Asked Questions (FAQs)
What is the main subject of United States Patent 10,722,502?
The main subject is the crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde (Compound 1).
How are the crystalline forms characterized in the patent?
The crystalline forms are characterized using differential scanning calorimetry (DSC) and X-ray powder diffraction (XRPD).
What are the therapeutic applications of the crystalline forms described in the patent?
The therapeutic applications include increasing oxygen affinity of hemoglobin S and treating oxygen deficiency associated with sickle cell anemia.
What is the significance of the patent's continuation applications and priority claims?
These indicate a continuous effort to refine and expand the claims related to Compound 1 and its crystalline forms over several years.
How does the patent impact the pharmaceutical industry?
The patent can lead to more effective and stable therapeutic agents for treating sickle cell anemia and influences licensing, collaboration, and litigation in the industry.
Cited Sources
- US Patent for Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde. Justia Patents.
- Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation. Google Patents.
- Patent Claims and Patent Scope. SSRN.
- Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde. Google Patents.
